MyCEI Login


Update on HIV-1 bNAbs for the Prevention, Therapy, and Cure of HIV


Published Date: 08/14/2023

Expiration Date: 07/11/2026

CE Credit: CME:1


Anti-HIV broadly neutralizing antibodies (bNAbs), alone or in combination, are some of the most exciting agents in the pipeline for the prevention, management, salvage, and potential cure of HIV. Dr. Marina Caskey, one of the most prominent researchers leading the way in this new field of immunotherapy, returns with an update on bNAbs in clinical development, and results from HIV-prevention trials utilizing bNAbs.


Marina Caskey,MD

Marina Caskey, MD is a Professor of Clinical Investigation at The Rockefeller University. Her work focuses on the development and clinical evaluation of novel immunotherapeutic strategies against infectious diseases, with a special emphasis on HIV. Dr. Caskey has led a series of early-phase clinical studies to evaluate the safety and efficacy of broadly neutralizing anti-HIV antibodies. These studies have revitalized this area of HIV research, which had been abandoned after first-generation antibodies failed to show significant effects in humans. Broadly neutralizing antibodies are now considered one of the most promising strategies to achieve HIV remission, as well as potential alternatives to antiretrovirals for both therapy and prevention. Dr. Caskey is also an attending physician in infectious diseases at Weill Cornell Medicine Center and an elected member of the American Society of Clinical Investigation.

Learning Objectives

  • Know about new anti-HIV broadly neutralizing antibodies in clinical development.
  • Understand results from two prevention efficacy studies (AMP trials) with VRC01, an HIV bNAb.
  • Be aware of recent clinical trials of engineered HIV bNAbs.

Continuing Education Credit Information